Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Finance

Sept. 12 Quick Takes: Nimbus draws $125M to advance pair of lead molecules

Plus new name, COVID-19 mAb for Adagio and updates from Horizon, Acadia, Chiesi and more

September 13, 2022 12:56 AM UTC

Two years after raising a $60 million crossover round, Nimbus Therapeutics LLC has turned to Bain Capital Life Sciences and SV Health Investors to lead a new $125 million private financing. The 13-year-old computational chemistry company, which launched with an asset-focused, partnership-heavy strategy but has increasingly focused on its internal pipeline in recent years, is conducting Phase IIb trials of allosteric TYK2 inhibitor NDI-034858 to treat psoriatic arthritis and psoriasis, and Phase I/II testing of HPK1 inhibitor to treat solid tumors.

A little more than two years after being spun out of Adimab LLC to develop mAbs to treat COVID-19, Adagio Therapeutics Inc. (NASDAQ:ADGI) is changing its name to Invivyd and will trade under the IVVD ticker symbol starting Tuesday. The biotech raised $825 million in just over a one-year span, including a $355.8 million IPO in August 2021, before the stock sank more than 80% last December after the company reported its lead COVID-19 mAb ADG20 showed a more than 300-fold reduction in neutralizing activity against the Omicron variant, a reversal from prior claims that the mAb was active against the strain. Separately on Monday, Invivyd said it selected NVD200, a combination of two mAbs, as its next lead candidate against COVID-19, with plans to enter the clinic in 1Q23. Invivyd had a market cap of $500 million on Monday and had reported $475 million in cash at June 30...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article